This clinical trial is focused on studying a condition known as Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), which can occur during pregnancy. FNAIT is a rare condition where the mother’s immune system mistakenly attacks the baby’s platelets, which are small blood cells that help with clotting. This can lead to low platelet counts in the baby, increasing the risk of bleeding. The study is testing a treatment called nipocalimab, which is given as a solution for infusion, meaning it is administered directly into the bloodstream through a vein. Nipocalimab is being compared to a placebo to see if it can reduce the risk of severe FNAIT in pregnancies that are considered at risk.

The purpose of the study is to evaluate whether nipocalimab is more effective than a placebo in reducing the risk of severe FNAIT. Participants in the study will receive either nipocalimab or a placebo, and the study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The study will follow the participants throughout their pregnancy and monitor the health of the baby up to the first week after birth. This will help determine if nipocalimab can safely and effectively reduce the risk of complications associated with FNAIT.

Throughout the study, the health of both the mother and the baby will be closely monitored. This includes regular check-ups and assessments to ensure the safety and well-being of both. The study aims to provide valuable information on the potential benefits of nipocalimab in managing FNAIT and improving outcomes for at-risk pregnancies. Participants will be contributing to important research that could lead to better treatment options for this condition in the future.